ミネソタ州における骨髄増殖性腫瘍の臨床試験
ミネソタ州内の拠点で、骨髄増殖性腫瘍に関する8件の研究が参加者を募集しています。
ミネソタ州内の都市
公式研究テキスト（英語）
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Mercy Hospital, Coon Rapids
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- 他8件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05564390Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- Mayo Clinic Rochester, Rochester
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/23更新 · NCT05320198Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Mercy Hospital, Coon Rapids
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- 他9件
被験者募集中第2相
18歳〜59歳 · 全性別 · 2026/09/22更新 · NCT05554406Project: Every Child for Younger Patients With Cancer
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
- Mayo Clinic in Rochester, Rochester
被験者募集中観察研究
25歳以下 · 全性別 · 2026/08/25更新 · NCT02402244Allo HSCT Using RIC and PTCy for Hematological Diseases
- Masonic Cancer Center at University of Minnesota, Minneapolis
被験者募集中第2相
75歳以下 · 全性別 · 2026/07/06更新 · NCT05805605Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
- Masonic Cancer Center at University of Minnesota, Minneapolis
被験者募集中第2相
60歳以下 · 全性別 · 2026/06/25更新 · NCT03314974Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms
- Mayo Clinic in Rochester, Rochester
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/22更新 · NCT05549661SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Duluth
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。